Nuvectis PharmaNVCT
Recorded

Nuvectis Pharma 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration48 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and welcome to the Nuvectis Pharma Third Quarter 2026 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the prepared remarks, we will conduct a question-and-answer session. As a reminder, this call is being recorded. I would like to now turn the call over to Ron Bentsur, Chairman and CEO of Nuvectis Pharma.

Ron BentsurChairman and CEO

Please go ahead. Thank you, and good morning, everyone.

Ron BentsurChairman and CEO

Before we begin, I would like to remind everyone that statements made during this call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and on our interpretation of information available to date, and they are subject to substantial risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the section titled Risk Factors in our quarterly report on Form 10-Q for the quarter ended September 30, 2026, and our other filings with the SEC. These risks are not exhaustive, and new risks emerge from time to time.

Ron BentsurChairman and CEO

Any forward-looking statements made on this call speak only as of today, Wednesday, November 4, 2026, and Nuvectis undertakes no obligation to update or revise them, except as required by law. Now let's get to the interesting part of this call. Today's the first time we're hosting a call alongside the release of our quarterly results, and the reason is simple. The third quarter was transformational for Nuvectis, and we have a great deal to share with you. We have transformed Nuvectis into a late-stage development company with the addition of two exciting drug candidates with best-in-class potential through our licensing agreement for ex-China rights with our new partner, Haisco. These additions have fundamentally changed the opportunity ahead of us.

Ron BentsurChairman and CEO

Our lead drug candidate, ciprocopan, which we also interchangeably refer to as NXP100, is an oral complement Factor B inhibitor for once-daily oral administration that is approved in China for the treatment of newly diagnosed paroxysmal nocturnal hemoglobinuria, or PNH in short, and in development for the treatment of other complement-mediated diseases, including an ongoing phase III study in IgA nephropathy, a phase II study in lupus nephritis, both being conducted in China by our partner, Haisco. The second drug, NXP200, is an oral brain-penetrant paradox-breaker BRAF inhibitor for the treatment of BRAF-mutated solid tumors, and I'll expand on these two products and on our legacy compound, NXP900, during the call. We closed the licensing deal with Haisco in late June, after which we completed a follow-on offering of $150 million in gross proceeds that was anchored by leading healthcare-dedicated institutional investors.

Ron BentsurChairman and CEO

Also in the third quarter, we placed approximately $37 million with a single healthcare-dedicated fund through our ATM facility. We ended the quarter with approximately $140 million in cash, which we expect will fund our operations into the second half of 2029, and importantly, beyond multiple value inflection points. Let's start with the key pipeline development highlights before taking a slightly deeper dive into our plans going forward. In July, ciprocopan, or NXP100, received its first marketing approval in China for the treatment of patients with PNH who were not previously treated with complement inhibitors. The approval was based on a phase III study in which NXP100 demonstrated clear superiority versus Soliris on the primary and all key secondary endpoints. A second marketing application for ciprocopan in China is currently under review.

Ron BentsurChairman and CEO

This application covers patients with PNH who were previously treated with C5 inhibitors and is supported by another very successful phase III study in this patient population. We expect Haisco to announce this approval in the first quarter of 2027. We are in active dialogue with the FDA about our development plan for PNH in the U.S. These discussions are going well, and we feel that the FDA is very engaged. We expect to provide an update on the FDA interaction by year-end. Several additional phase II and phase III studies with NXP100 are ongoing. We are also carefully watching the phase II and phase III studies being conducted with Fabhalta, or iptacopan, Novartis's twice-a-day oral complement Factor B inhibitor. All these study results could provide an excellent roadmap for the additional indications that we may want to pursue with NXP100.

Ron BentsurChairman and CEO

We expect the coming months to be packed with important relevant news on the NXP100 front. Turning to NXP200. In September, the drug candidate was granted breakthrough designation in China for the treatment of BRAF V600 mutant recurrent or progressive high-grade glioma. In October, NXP200 was the subject of an oral presentation at the ESMO conference. Updated phase I-B data from a Haisco study in China demonstrated deep and durable single-agent activity with NXP200, including complete responses in patients with recurrent or progressive gliomas. Importantly, responses were also observed in patients previously treated with a BRAF inhibitor. Both of these aspects, complete responses and responses in BRAF relapse patients, could be meaningful points of differentiation for NXP200 compared to the other second-generation BRAF inhibitors in development. The emerging clinical profile for NXP200 demonstrates best-in-class potential.

Ron BentsurChairman and CEO

NXP200 is currently being investigated in a broad clinical program in China to unlock its full therapeutic potential. For our legacy NXP900 oncology candidate, the phase I-B program continues. This includes ongoing osimertinib and lorlatinib combination studies, and the planned investigator-initiated study of NXP900 in combination with the newly approved KRAS inhibitor, daraxonrasib, in pancreatic cancer. This investigator-initiated study will be led by two top medical centers in the country. As you can see, we are off to a very good start on all fronts since completing the licensing deal in late June. Now let's take a closer look at our plans for each program. Importantly, we are doing so from a very strong financial position with estimated cash runway into the second half of 2029. Let's start with ciprocopan or NXP100. NXP100 inhibits Factor B of the complement system.

Ron BentsurChairman and CEO

Factor B is a key component of the alternative pathway, one of three pathways of the complement system. By inhibiting Factor B, NXP100 blocks the amplification of the alternative pathway while preserving the other two. PNH and other complement-mediated diseases result from uncontrolled complement activation. Blocking different targets within the complement system has proven to be a very successful strategy. Treatments like Soliris, Ultomiris, and Fabhalta are approved in several different indications and generate significant revenue. As I mentioned, the first approval of NXP100 in China was based on a randomized head-to-head phase III study versus Soliris in treatment-naive PNH patients. NXP100 was superior to Soliris on the primary endpoint and all key secondary endpoints. The second marketing application in China that is currently under review is based on a phase III study conducted in patients with PNH who failed treatment with a C5 inhibitor.

Ron BentsurChairman and CEO

This study also met the primary endpoint and key secondary endpoints with plenty of room to spare. It is important to mention that the overall hemoglobin increase demonstrated by NXP100 in the phase III studies conducted were rather unprecedented, with average hemoglobin increases of 5 and 4.4 grams per deciliter in the treatment-naive and previously treated studies, respectively. Importantly, the safety profile of NXP100 appears consistent with that of other complement inhibitors. So what does the opportunity in PNH look like for NXP100? The PNH market is estimated to be around $5 billion today and is expected to double within the next eight to 10 years. Historically, this market has been dominated by the injectable C5 inhibitors, which were the centerpiece of AstraZeneca's $39 billion acquisition of Alexion in 2021.

Ron BentsurChairman and CEO

Factor B inhibitors offer the potential for better efficacy compared to the C5 inhibitors, along with the convenience of oral administration. With much better efficacy and this convenience advantage, we expect the Factor B inhibitors to become the leading class in PNH over time. As of today, the only FDA-approved Factor B inhibitor is Fabhalta from Novartis. Fabhalta is approved for PNH, IgA nephropathy, and C3G, a smaller nephrology indication, and is off to a fast start. It is on an annualized run rate of approximately $1 billion already, and this is about two years out of the gate. We see a potentially substantial advantage for NXP100 in its once-daily dosing compared to the twice per day for Fabhalta. This convenience advantage could be very meaningful and should not be underestimated in chronic diseases like PNH that require continuous lifelong treatment.

Ron BentsurChairman and CEO

I think most of you would agree that there is nothing easier for a patient suffering from a condition requiring lifelong therapy than a once-a-day oral treatment. As you have likely gathered by now, PNH is only the beginning. In China, NXP100 is in an ongoing phase III study in IgA nephropathy, following a successful 24-week phase II study. In this study, NXP100 demonstrated a statistically significant and clinically meaningful reduction in proteinuria. Importantly, the study also showed an almost three-point increase in eGFR in the NXP100 arm compared to a 1.5-point decline in the placebo arm over this 24-week time horizon. We know that there is a lot of excitement around the APRIL/BAFF class of drugs in the IgA nephropathy space, and for good reason.

Ron BentsurChairman and CEO

In IgA nephropathy, the new standard established by the best APRIL/BAFF drugs is the ability to stabilize eGFR long-term, and that is considered disease-modifying. It appears that Fabhalta comes up just shy of being able to do that, whereas NXP100, based on the phase II data generated, definitely has the potential to deliver that. This is where the favorable pharmacokinetic and pharmacodynamic profile of NXP100 versus Fabhalta may be coming into play. Hence, NXP100 has the potential to deliver this competitive efficacy, which can compare to the best APRIL/BAFFs, but with the clear convenience advantage of once-daily oral dosing versus the APRIL/BAFFs, which are all injectables. Together, the PNH and IgA nephropathy markets alone are estimated to exceed $20 billion within the next 10 years. Our priority is to advance NXP100 towards a marketing application in the U.S. for PNH.

Ron BentsurChairman and CEO

We also see significant potential in additional indications. Our U.S. regulatory efforts in PNH are well underway. With two positive phase III studies from China, we believe we have a strong clinical data package. This puts us in a good position as we work with the FDA to define the U.S. regulatory path. We continue to have constructive dialogue with the FDA, which, as I mentioned before, we feel is very engaged. We expect to provide an update on the U.S. regulatory path before year-end. In addition, we are planning to submit an IND for another indication outside of PNH later this year. We also plan to initiate clinical trials in additional indications in the first half of 2027. Novartis is currently running five phase II and phase III clinical trials for Fabhalta in additional indications beyond the three approvals that they already have.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day